corest inhibitor tng260
Generic: CoREST Inhibitor TNG260
corest inhibitor tng260: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Tango Therapeutics, Inc. (TNGX) | Phase 1 |
Clinical Trials (1)
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors
Frequently asked questions
Who is developing corest inhibitor tng260?
corest inhibitor tng260 is being developed by Tango Therapeutics, Inc..
How many clinical trials involve corest inhibitor tng260?
BioSniper tracks 1 clinical trial involving corest inhibitor tng260.
Get deeper analysis on corest inhibitor tng260
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis